Opioid and opioid-like compounds and uses thereof

Details Opioid and opioid-like compounds and uses thereof Opioid and opioid-like compounds and uses thereof

2011-04-12

2011-04-12

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S074000

Reexamination Certificate

active

07923454

ABSTRACT:
The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations containing the same and methods of use thereof. Uses of the present invention include, but are not limited to, use for the prevention and treatment of septic shock and other disorders. The compounds described herein can be water soluble and can act through mechanisms mediated through pathways other than opiate receptors.

REFERENCES:
patent: 3275638 (1966-09-01), Sawa et al.
patent: 3764606 (1973-10-01), Akkerman et al.
patent: 3793329 (1974-02-01), Merz
patent: 3819635 (1974-06-01), Pachter et al.
patent: 3872127 (1975-03-01), Merz et al.
patent: 3923987 (1975-12-01), Merz et al.
patent: 3936463 (1976-02-01), Behner et al.
patent: 4029798 (1977-06-01), Yamamoto et al.
patent: 4128548 (1978-12-01), Akkerman et al.
patent: 4161597 (1979-07-01), Olofson et al.
patent: 4228285 (1980-10-01), Montzka et al.
patent: 4230712 (1980-10-01), Kotick et al.
patent: 4267182 (1981-05-01), Holaday et al.
patent: 4272541 (1981-06-01), Kotick et al.
patent: 4288444 (1981-09-01), Akkerman et al.
patent: 4388463 (1983-06-01), Brossi et al.
patent: 4390699 (1983-06-01), Brossi et al.
patent: 4673679 (1987-06-01), Aungst et al.
patent: 4912114 (1990-03-01), Revesz
patent: 5071985 (1991-12-01), Andre et al.
patent: 5219861 (1993-06-01), Kanematsu et al.
patent: 5354758 (1994-10-01), Lawson et al.
patent: 5504208 (1996-04-01), Sobotik et al.
patent: 5607941 (1997-03-01), Merz et al.
patent: 5731318 (1998-03-01), Carter et al.
patent: 5780479 (1998-07-01), Kim
patent: 5912347 (1999-06-01), Hudlicky et al.
patent: 6150524 (2000-11-01), Hartmann et al.
patent: 6166211 (2000-12-01), Cain et al.
patent: 6242604 (2001-06-01), Hudlicky et al.
patent: 6271239 (2001-08-01), Portoghese
patent: 6323212 (2001-11-01), Nagase et al.
patent: 2072814 (1993-01-01), None
patent: 2 238 839 (1974-02-01), None
patent: 2238839 (1974-02-01), None
patent: 0377272 (1990-07-01), None
patent: 0242417 (1993-02-01), None
patent: 0577847 (1994-01-01), None
patent: 0632041 (1995-01-01), None
patent: 0663401 (1995-07-01), None
patent: 1038732 (1966-08-01), None
patent: 1077711 (1967-08-01), None
patent: 2175898 (1986-12-01), None
patent: 98/05667 (1998-02-01), None
patent: 00/56735 (2000-09-01), None
patent: 02/16367 (2002-02-01), None
patent: 02/36573 (2002-05-01), None
patent: 03/037340 (2003-05-01), None
Kim, Hyoung-Chun et al. “Anticonvulsant Effects of New Morphinan Derivatives”,Bioorg. Med. Chem. Lett. (2001), 11: 1651-1654.
Grauert, Matthias et al. “Synthesis and Structure-Activity Relationship of 6,7-Benzomorphan Derivatives as Antagonists of the NMDA Receptor-Channel Complex”,J. Med. Chem. (1997), 40: 2922-2930.
Hamabe, Wakako et al. “(−)1-(Benzofuran-2-y1)-2-propylaminopentane Shows Survival Effect on Cortical Neurons Under Serum-free Condition Through Sigma Receptors”,Cell. Mol. Neurobiol. (2000), 20(6): 695-702.
May, Everette L. et al. “Synthesis and in Vitro and in Vivo Activity of (−)-(1R,5R,9R)-and (+)-(1S,5S,9S)-N-Alkenyl-,-N-Alkynyl-, and—N-Cyanoalkyl-5,9-dimethyl-2′-hydroxy-6,7-benzomorphan Homologues”,J. Med. Chem. (2000), 43(26): 5030-5036.
Chao, Chun C, et al. “Opiates, Glia, and Neurotoxicity”,Adv. Exp. Med. Biol. (1996), 402: 29-33.
McGeer, Edith G. and Patrick L. McGeer. “The Role of the Immune System in Neurodegenerative Disorders”,Movement Disorders(1997), 12: 855-858.
Liu, Bin et al. “Naloxone Protects Rat Dopaminergic Neurons against Inflammatory Damage through Inhibition of Microglia Activation and Superoxide Generation”,J. Pharmacol. Exp. Therap. (2000), 293: 607-617.
“Reactive Oxygen Species (ROS)”,R&D Systems—Mini-Review: Reactive Oxygen Species(ROS), copyright 2002, R&D Systems. www.rndsystems.com.
Channon, K. M. and T.J. Gutzik, “Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors”,J. Physiol. Pharmacol. (2002), 53(4): 515-524.
Henrotin, Y. E. et al. “The role of reactive oxygen species in homeostasis and degradation of cartilage”,OsteoArthritis and Cartilage(2003), 11: 747-755.
Arzimanoglou, A. et al. “Epilepsy and neuroprotection: An illustrated review article”,Epileptic Disord. (2002), 3: 173-182.
Seidman, M.D. et al, “Biologic activity of mitochondrial metabolites on aging and age-related hearing loss”,Am. J. Otol. (2000), 21(2): 161-167.
McCord, J. M. and I. Fridovich. “Superoxide Dismutase: An Enzymic Function for Erythrocuprien (Hemocuprein)”,J. Biol. Chem. (1969), 244: 6049-6055.
Feldmann, M. and R.N. Maini. “Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies”,Joint Bone Spine(2002), 69: 12-18.
Lipsky, P.E. et al. “Infliximab and methotrexate in the treatment of rheumatoid arthritis”,N. Engl. J. Med. (2000), 343:1594-1602.
Newton, R. C. and C. P. Decicco. “Therapeutic potential and strategies for inhibiting tumor necrosis factor-α.”,J. Med. Chem. (1999), 42: 2295-2314.
Preiser et al. “Methylene blue administration in septic shock: a clinical trial”;Crit. Care Med. (1995), 23: 259-264.
Gachot, B. et al. “Short term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock”,Intensive Care Med. (1995), 21: 1027-1031.
Vincent, J. L. et al. “Clinical trials of Immunomodulatory therapies in severe sepsis and septic shock”,CID(2002), 34: 1084-1093.
Wolfe, John P. and Stephen L. Buchwald. “Improved Functional Group Compatibility in the Palladium-Catalyzed Amination of Aryl Bromides”,Tetrahedron Letters(1997), 38: 6359-6362.
Ahman, Jens and Stephen L. Buchwald. “An Improved Method for the Palladium-Catalyzed Amination of Aryl Triflates”,Tetrahedron Letters(1997), 38: 6363-6366.
Tyle, Praveen. “Iontophoretic Devices for Drug Delivery”;Pharmaceutical Research(1986), 3(6): 318.
Remington,The Science and Practice of Pharmacy, Easton, PA. Mack Publishing Co. 9thEd., 1995.
Orlek, B.S. et al. “Comparison of Azabicyclic Esters and Oxadiazoles as Ligands for the Muscarinic Receptor”,J. Med. Chem. (1991), 34(9): 2726-2735.
Wu, Chin-Chen et al. “Terbutaline Prevents Circulatory Failure and Mitigates Mortality in Rodents with Endotoxemia”,Shock(2000), 14: 60-67.
Wu, Chin-Chen et al. “Evidence for Inducible Nitric Oxide Synthase in Spontaneously Hypertensive Rats”,Biochem. Biophys. Res. Commun. (1996), 228: 459-466.
Chen, A. et al. “Glomerular Localization of Nephritogenic Protein Complexes on a Nonimmunologic Basis”,Lab. Invest. (1992), 67: 175-185.
Olofson, R. A. et al. “A new reagent for the selective, high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine”,J. Org. Chem. (1984), 49(11): 2081-2082.
Schmidhammer, H. et al. “Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (−)-14-Methoxy-N-Methylmorphinan-6-ones”J. Med. Chem. (1984), 27(12): 1575-1579.
Coop, A. et al. “Delta opioid binding selectivity of 3-Ether analogs of Naltrindole”,Bioorg. Med. Chem. Lett. (1999), 9(24): 3435-3438.
Filer, C.N. et al. “Reduction of the N-Propargyl group with Tritium. General procedure for the preparation of N-′2,3-3H Allyl Opiate ligands at high specific activity”,J. Org. Chem. (1981), 46: 4968-4970.
Jacobson, A. E. et al. “Paradoxical effects of N-cyanoalkyl substituents upon the activities of several classes of opioids”,J. Med. Chem. (1979), 22(3): 328-331.
Koolpe, G.A. et al. “Diastereomeric 6-Desoxy-6-spiro-alpha-methylene-gamma-butyrolactone Derivative of Naltrexone and Oxymorphone . . . ”,J. Med. Chem. (1984), 27: 1718-1723.
“Morphinan”, pp.

Affiliated with

Also associated with

Rating

Opioid and opioid-like compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Opioid and opioid-like compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opioid and opioid-like compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2692983